Business
GENFIT to Present Latest ACLF Research at EASL Congress 2025
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 5, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announces its participation at the European Association for the Study of the Liver (EASL) Annual Congress 2025 with six posters presenting the latest research in ACLF and multiple events highlighting the growing importance of ACLF within the he
About this update from Genfit Sa
[{"type":"text","content":"Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 5, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announces its participation at the European Association for the Study of the Liver (EASL) Annual Congress 2025 with six posters presenting the latest research in ACLF and multiple events highlighting the growing importance of ACLF within the hepatology community.","length":519,"tagName":"p"},{"type":"text","content":"I. PostersSix posters have been accepted for presentation at EASL Congress mainly covering several of GENFIT’s assets positioned in ACLF and, including, GENFIT’s latest work on Real-World data in ACLF.","length":204,"tagName":"p"},{"type":"text","content":"ACLFPoster #1: Intraperitoneal administration of investigational drug VS-01 captures accumulated metabolites in patients with acutely decompensated liver cirrhosisPoster: FRI-172","length":182,"tagName":"p"},{"type":"text","content":"Author/s: Olaf Tyc, Bérénice Alard, Meriam Kabbaj, Jérémy Magnanensi, Martin Sebastian Schulz, Sabine Klein, Robert Schierwagen, Sakina Sayah Jeanne, Stéphanie Ferreira, Dean Hum,Bart Staels, Katharina Staufer, Jonel Trebicka, Frank Erhard UschnerSession: Cirrhosis and its complications: ACLF and Critical IllnessPoster #2: Efficacy of the apoptosis-signal-regulating kinase 1 (ASK1) inhibitor SRT-015 in vivo and in vitro pathogen-associated molecular patterns (PAMPs)-induced disease modelsPoster: THU-187","length":514,"tagName":"p"},{"type":"text","content":"Author/s: Vanessa Legry, Manon Clarisse, Simon Debaecker, Nicolas Stankovic Valentin, Philippe Poulain, Dean Hum, Bart Staels, Joan Claria, Sakina Sayah JeanneSession: Poster – Cirrhosis and its complications: Experimental and pathophysiologyPoster #3: CLM-022, a dual inhibitor of priming and activation steps of NLRP3 inflammasome, as a potential treatment for acute and chronic inflammatory late-stage liver diseasesPoster: THU-152","length":439,"tagName":"p"},{"type":"text","content":"Author/s: Hana El Khatib, Alexandra Caron, Elodie Delecroix, Victor Launay, Maryse Malysiak, Valérie Daix, Simon Debaecker, Guillaume Vidal, Dean Hum, Bart Staels, Sakina Sayah JeanneSession: Cirrhosis and its complications: Experimental and pathophy...